Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Document Type
Article
Publication Date
8-17-2020
Keywords
JGM, JAXCC
JAX Source
Neuro Oncol 2020 Aug 17; 22(8):1073-1113
Volume
22
Issue
8
First Page
1073
Last Page
1113
ISSN
1523-5866
PMID
32328653
DOI
https://doi.org/10.1093/neuonc/noaa106
Abstract
Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.
Recommended Citation
Wen P,
Weller M,
Lee E,
Alexander B,
Barnholtz-Sloan J,
Barthel F,
Batchelor T,
Bindra R,
Chang S,
Chiocca E,
Cloughesy T,
DeGroot J,
Galanis E,
Gilbert M,
Hegi M,
Horbinski C,
Huang R,
Lassman A,
Le Rhun E,
Lim M,
Mehta M,
Mellinghoff I,
Minniti G,
Nathanson D,
Platten M,
Preusser M,
Roth P,
Sanson M,
Schiff D,
Short S,
Taphoorn M,
Tonn J,
Tsang J,
Verhaak R,
von Deimling A,
Wick W,
Zadeh G,
Reardon D,
Aldape K,
van den Bent M.
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 2020 Aug 17; 22(8):1073-1113